Tempus, Kartos Therapeutics to Develop CDx for Skin Cancer Therapy
The test will run on Tempus' xT platform and will be used to identify patients with TP53 wild-type Merkel cell carcinoma who may be eligible for treatment with the drug.
Ambitions and timelines diverge, but innovators of expanded panels see broad testing as valuable to current patients and future precision oncology innovation.
Tempus, Intermountain Healthcare Strike Precision Cancer Research Alliance
Intermountain will use Tempus' next-generation sequencing-based cancer assay to study patient samples to advance research into precision patient care.
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
Aadi Bioscience Inks NGS Lab Partnerships to Screen Solid Tumor Patients for Fyarro Trial
The firm has partnered with Foundation Medicine, Tempus, and others to ID patients with TSC1 and TSC2 mutations for the Phase II PRECISION 1 clinical trial.